Preparation, characterizaton, and biodistribution study of technetium-99m-labeled leuprolide acetate-loaded liposomes in ehrlich ascites tumor-bearing mice

AAPS Journal

Volumn 6, Issue 1, 2004, Pages

  Arulsudar, N ^a   Subramanian, N ^a   Mishra, P ^b   Chuttani, K ^b   Sharma, R K ^b   Murthy, R S R ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Biodistribution; Gamma imaging; Leuprolide acetate; Sterically stabilized liposomes; Technetium 99m

Indexed keywords

LEUPRORELIN; LIPOSOME; LIPOSOME TC 99M; PENTETIC ACID; PEPTIDE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHELATION; CIRCULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; EHRLICH ASCITES TUMOR; EVAPORATION; GAMMA SCINTIGRAPHY; IMAGE ANALYSIS; IMAGING SYSTEM; IN VITRO STUDY; ISOTOPE LABELING; LIVER; MALE; MEDICAL DOCUMENTATION; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA CLEARANCE; RETICULOENDOTHELIAL SYSTEM; SOLID TUMOR; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG DELIVERY SYSTEM; METABOLIC CLEARANCE RATE; METABOLISM; RABBIT; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, EHRLICH TUMOR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; LEUPROLIDE; LIPOSOMES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; RABBITS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 34248662937     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps060105     Document Type: Article

References (40)

1. Chrisp P, Sorkin EM. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1991;1:487-509.
2. Oesterling JE. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia. J Androl. 1991;12:381-388.
3. Tunn UW, Bargelloni U, Cosciani S, Fiacavento G. Guazzieris, Pagano F. Comparison of LHRH analogue 1 month depot and 3-month depot by their hormonal levels and pharmacokinetic profile in patients with advance prostate cancer. Urol Int. 1998;60(suppl 1):9-16.
4. Plosker GL, Brodgen RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostate cancer, endometriosis and other sex hormone related disorders. Drugs. 1994;48 (6):930-967.
5. Garnick MB. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281-1286.
6. Okada H, Sakura Y, Kawaji T, Yashiki T, Mima H. Regression of rat mammary tumors by a potent leutinizing hormone releasing hormone administered vaginally. Cancer Res. 1983;43:1869-1874.
7. 6 analogue of LHRH. Proc Natl Acad Sci U S A. 1981;78:6509-6512.
8. Nagai N, Oshita T, Mukai K, Shiroyama Y, Shigemasa K, Ohama K. GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med. 2002;10:593-597.
9. Dondi D, Limnota P, Moretti RM. Marelli MM, Garattini E, Mota M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen independent prostate cancer cell line DU145: evidence for an autocrine-inhibitory loop. Cancer Res. 1994;54:4091-4095.
10. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab. 1992;75:207-212.
11. Dondi D, Moretti RM, Marelli MM, et al. Growth inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer. 1998;76:506-511.
12. Schally AV. Hypothalamic hormones from neuroendocrinology to cancer therapy. Anticancer Drugs. 1994;5:115-130.
13. Loop SM, Gorder CA, Lewis SM, Saiers JH, Drivdahl RH, Ostenson RC. Growth inhibition of human prostatic cancer cells by an agonist of gonadotropin-releasing hormone. Prostate. 1995;26:179-188.
14. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer. 1990;62:96-99.
15. Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol. 1994;106:145-149.
16. Anderson PM, Hanson DC, Hasz DE, Halet MR, Blazar BR, Ochoa AC. Cytokines in liposomes: Preliminary studies with IL-1, IL-2, IL-6, GM-CSF and Interferon Gamma. Cytokine. 1994;6:92-101.
17. Meyer J, Whitcomb L, Collins D. Efficient encapsulation of proteins within liposomes for slow release in vivo. Biochem Biophys Res Commun. 1994;199:433-438.
18. Perez-Soler R. Liposomes as carriers of antitumor agents; towards a clinical reality. Cancer Treat Rev. 1989;16:67-82.
19. Gabizon A. Liposomes as a drug delivery system in cancer chemotherapy. In: Roerdink F, Kroon A, eds. Drug Carrier Systems, Horizons in Biochemistry and Biophysics. New York, NY: John Wiley & Sons. Vol 9. 1989:185-211.
20. Gabizon AA, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst. 1989;81:1484-1488.
21. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992;52:6774-6781.
22. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in-vivo. Biochim Biophys Acta. 1991;1066:29-36.
23. Allen TM, Mehra T, Hansen C, Chin YC. Stealth liposomes: and improved sustained release system for 1-beta-D arabinofuranosylcytosine. Cancer Res. 1992;52:2431-2439.
24. Allen TA, Hansen C. Pharmacokinetics of stealth vs. conventional liposomes: Effect of dose. Biochim Biophys Acta. 1991;1068:133-141.
25. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse evaporation. Proc Natl Acad Sci U S A. 1978;75:4194-4198.
26. New RRC. Liposomes: a practical approach. In: New RRC, ed. Preparation of Liposomes. New York, NY: Oxford University Press; 1990:95-96.
27. Adjei AL, Hsu L. Leuprolide and other LHRH analogues. In: John YW, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. New York, NY: Plenum Press; 1993:154-180.
28. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
29. 99mTc] technetium-labeled liposomes in normal and tumour-bearing rats: Biochem Soc Trans. 1977;5(1):290-229.
30. Theobald AE. Theory and practice. In: Sampson CB, ed. Textbook of Radiopharmacy. New York, NY: Gorden and Breach; 1990:127-128.
31. Wu MS, Robbins JC, Ponpipom MM, Shen TV. Modified in vivo behaviour of liposomes containing synthetic glycolipids. Biochim Biophys Acta. 1981;674:19-29.
32. Lo Y, Rahman Y. Protein location in liposomes, a drug carrier: a prediction by differential scanning calorimetry. J Pharm Sci. 1995;84:805-813.
33. Schafer H, Schmidt W, Lachmann U. Preparation and properties of GnRh-loaded multilamellar liposomes. Pharmazie. 1987;42:674-677.
34. Huang L. Covalently attached polymers and glycans to alter the biodistribution of liposomes. J Liposome Res. 1992;2:289-291.
35. Litzinger CD, Buiting MJA, Rooijen VN, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta. 1994;1190:99-107.
36. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235-237.
37. Saha GB. Methods of radiolabeling. In: Saha GB, ed. Physics and Radiobiology of Nuclear Medicine. New York, NY: Springer-Verlag; 1993:100-106.
38. Gabizon G, Papahadjopoulos D. Liposome formulation with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85:6949-6953.
39. Gabizon G, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987-992.
40. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253-256.